All contributors
Onconephrology contributor
Herrmann, Sandra M
Primarily Anticancer drug nephrotoxicity#19 of 47 recognizedHonor roll
- #4 in Anticancer drug nephrotoxicity
- #1 in Checkpoint-inhibitor kidney injury
40
Clinical papers
1,531
Citations (iCite)
6 / 16
First / senior author
2010–2026
Active years
Output over time
Clinical corpus papers per year — peak 8 in 2025.
- 2010: 1 paper
- 2011: 1 paper
- 2012: 1 paper
- 2015: 1 paper
- 2019: 1 paper
- 2020: 4 papers
- 2021: 2 papers
- 2022: 7 papers
- 2023: 4 papers
- 2024: 7 papers
- 2025: 8 papers
- 2026: 3 papers
20102026
Subfield mix
Clinical papers by onconephrology subfield (a paper can count in more than one).
Anticancer drug nephrotoxicity24
Checkpoint-inhibitor kidney injury22
Onco-nephrology (general)8
MGRS & paraprotein kidney disease7
Myeloma cast nephropathy6
Cellular therapy renal effects3
Frequent collaborators
Other recognized contributors who most often share corpus papers with Herrmann (shared-paper count).
Agents they study
Catalog agents whose clinical kidney literature lists Herrmann among the leading contributors.
Verify
Representative recent papers, and this author’s full PubMed bibliography.
A code-tallied bibliometric profile from PubMed + NIH iCite, restricted to human/clinical papers across a 15,329-article corpus (regenerated 2026-08-02). Recognition of published contribution — not a verdict on merit or influence, and not medical advice.